Budget Impact Analysis of Hyaluronic Acid Viscosupplementation for Knee Osteoarthritis in Colombia
Author(s)
DAYSI JOHANA SANMARTIN DURANGO, II, Msc1, Maria Alejandra Barrios Mercado, Esp2, Juan Sebastian Salazar, Msc3, Andrey Rojas, Msc4, Maria Consuelo Prieto, Esp5, Maria Jose Pareja, Msc6, Fabian A. Davila, Sr., PhD7.
1Research, Sapyens, Sabaneta, Colombia, 2Universidad del Norte, Barranquilla, Colombia, 3Sapyens, Bogotá, D.C., Colombia, 4Adium, Bogota, Colombia, 5Adium, Bogotá, D.C., Colombia, 6Market access, Adium, BOGOTA D.C., Colombia, 7Adium, Bogotá, Colombia.
1Research, Sapyens, Sabaneta, Colombia, 2Universidad del Norte, Barranquilla, Colombia, 3Sapyens, Bogotá, D.C., Colombia, 4Adium, Bogota, Colombia, 5Adium, Bogotá, D.C., Colombia, 6Market access, Adium, BOGOTA D.C., Colombia, 7Adium, Bogotá, Colombia.
OBJECTIVES: To estimate the budget impact of increasing utilization of multidose hyaluronic acid viscosupplementation among knee osteoarthritis patients aged ≥45 years requiring joint replacement intervention within Colombia's health benefit package.
METHODS: A budget impact model was developed adopting the Colombian healthcare payer perspective over a 5-year time horizon (2025-2029). The eligible population comprised patients aged ≥45 years with knee osteoarthritis indicated for arthroplasty, estimated at 4,921 incident cases annually based on epidemiological data. Treatment-specific annual arthroplasty probabilities were extracted through focused literature review: hyaluronic acid (4.2%), multimodal analgesia (12.8%), platelet-rich plasma (5.1%), and corticosteroids (8.4%). Resource utilization patterns were derived from clinical practice guidelines and validated through structured expert elicitation. Unit costs were sourced from SISMED 2023 pharmaceutical pricing database and the UPC sufficiency technical database, inflated to 2023 values. Market uptake scenarios modeled increased utilization from current practice patterns, reflecting clinical expert consensus on feasible adoption expansion. Direct medical costs were estimated using top-down microcosting methodology and converted to USD (exchange rate: 4,081.15 COP/USD).
RESULTS: Budget impact analysis revealed progressive cost savings favoring hyaluronic acid implementation. Incremental annual savings ranged from USD 3.6 million (Year 1) to USD 29.9 million (Year 5), yielding cumulative savings of USD 80.9 million over the analytic horizon. Cost offsets primarily resulted from reduced arthroplasty incidence relative to comparator therapies. The model demonstrated exponential savings trajectory with accelerated cost reduction between Years 2-4, indicating enhanced economic efficiency with market maturation.
CONCLUSIONS: Expanding utilization of multidose hyaluronic acid viscosupplementation represents a cost-saving strategy for knee osteoarthritis management within Colombia's healthcare system. Robust sensitivity analyses confirmed negative budget impact across all evaluated scenarios, supporting initiatives to increase access and utilization. The intervention's capacity to defer high-cost surgical procedures while maintaining clinical effectiveness establishes strong economic rationale for utilization optimization and clinical pathway enhancement.
METHODS: A budget impact model was developed adopting the Colombian healthcare payer perspective over a 5-year time horizon (2025-2029). The eligible population comprised patients aged ≥45 years with knee osteoarthritis indicated for arthroplasty, estimated at 4,921 incident cases annually based on epidemiological data. Treatment-specific annual arthroplasty probabilities were extracted through focused literature review: hyaluronic acid (4.2%), multimodal analgesia (12.8%), platelet-rich plasma (5.1%), and corticosteroids (8.4%). Resource utilization patterns were derived from clinical practice guidelines and validated through structured expert elicitation. Unit costs were sourced from SISMED 2023 pharmaceutical pricing database and the UPC sufficiency technical database, inflated to 2023 values. Market uptake scenarios modeled increased utilization from current practice patterns, reflecting clinical expert consensus on feasible adoption expansion. Direct medical costs were estimated using top-down microcosting methodology and converted to USD (exchange rate: 4,081.15 COP/USD).
RESULTS: Budget impact analysis revealed progressive cost savings favoring hyaluronic acid implementation. Incremental annual savings ranged from USD 3.6 million (Year 1) to USD 29.9 million (Year 5), yielding cumulative savings of USD 80.9 million over the analytic horizon. Cost offsets primarily resulted from reduced arthroplasty incidence relative to comparator therapies. The model demonstrated exponential savings trajectory with accelerated cost reduction between Years 2-4, indicating enhanced economic efficiency with market maturation.
CONCLUSIONS: Expanding utilization of multidose hyaluronic acid viscosupplementation represents a cost-saving strategy for knee osteoarthritis management within Colombia's healthcare system. Robust sensitivity analyses confirmed negative budget impact across all evaluated scenarios, supporting initiatives to increase access and utilization. The intervention's capacity to defer high-cost surgical procedures while maintaining clinical effectiveness establishes strong economic rationale for utilization optimization and clinical pathway enhancement.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE87
Topic
Economic Evaluation, Health Technology Assessment, Real World Data & Information Systems
Topic Subcategory
Budget Impact Analysis
Disease
Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), No Additional Disease & Conditions/Specialized Treatment Areas